Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469190 | 1.00 | TGFBR1 (0.38) | TGFBR1S1PR4AAK1PDE4BKDM4E | |
| SCHEMBL12958179 | 0.83 | MCHR1 (0.40) | TGFBR1S1PR4AAK1PDE4BKDM4E | |
| SCHEMBL2127198 | 0.78 | S1PR4 (0.57) | S1PR4KDM4ENPC1RAB9ALMNA | |
| SCHEMBL5211096 | 0.76 | NCF1 (0.48) | — | |
| SCHEMBL20869211 | 0.75 | PDE4B (0.48) | TGFBR1PDE4BKDM4ECXCR4LMNA | |
| SCHEMBL24975462 | 0.75 | SMN1; SMN2 (0.52) | SYKNPC1RAB9ALMNA | |
| SCHEMBL24975461 | 0.74 | AAK1 (0.35) | TGFBR1AAK1PDE4BSYK | |
| SCHEMBL4484041 | 0.70 | KDM4E (0.39) | KDM4ECXCR4GAANPC1RAB9A | |
| SCHEMBL25601599 | 0.70 | PDE4B (0.39) | TGFBR1PDE4BKDM4ECXCR4GAA | |
| SCHEMBL15473270 | 0.69 | PDE5A (0.39) | AAK1PDE4BKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | TGFBR1 4359/4885S1PR4 102/4885AAK1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.